Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
— Novel Oral Biologic Designed to Protect Patients from C. difficile Infection Associated with Systemic Antibiotics — ROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR […]
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program Read More »